Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10549-017-4262-0 http://scihub22266oqcxt.onion/10.1007/s10549-017-4262-0 C5487706!5487706 !28451965     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28451965 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Breast+Cancer+Res+Treat 2017 ; 164 (2 ): 461-466 Nephropedia Template TP {{tp|p=28451965 |t=2017. A breast cancer gene signature for indolent disease |pdf=|usr=}}{{28451965 }} gab.com Text A breast cancer gene signature for indolent disease JO: Breast Cancer Res Treat http://www.kidney.de/pget.php?&tw=1&pmid=28451965 #FOAvip PURPOSE: Early-stage hormone-receptor positive breast cancer is treated with endocrine therapy and the recommended duration of these treatments has increased over time. While endocrine therapy is considered less of a burden to patients compared to chemotherapy, long-term adherence may be low due to potential adverse side effects as well as compliance fatigue. It is of high clinical utility to identify subgroups of breast cancer patients who may have excellent long-term survival without or with limited duration of endocrine therapy to aid in personalizing endocrine treatment. METHODS: We describe a new ultralow risk threshold for the 70-gene signature (MammaPrint) that identifies a group of breast cancer patients with excellent 20 year, long-term survival prognosis. Tumors of these patients are referred to as "indolent breast cancer." We used patient series on which we previously established and assessed the 70-gene signature high-low risk threshold. RESULTS: In an independent validation cohort, we show that patients with indolent breast cancer had 100% breast cancer-specific survival at 15 years of follow-up. CONCLUSIONS: Our data indicate that patients with indolent disease may be candidates for limited treatment with adjuvant endocrine therapy based on their very low risk of distant recurrences or death of breast cancer. Twit Text FOAVip A breast cancer gene signature for indolent disease ????Breast Cancer Res Treat http://www.kidney.de/pget.php?&tw=1&pmid=28451965 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28451965 #FOAvip English Wikipedia <ref>{{Cite pmid|28451965 }}</ref> A breast cancer gene signature for indolent disease #MMPMID28451965 Delahaye LJMJ ; Drukker CA ; Dreezen C ; Witteveen A ; Chan B ; Snel M ; Beumer IJ ; Bernards R ; Audeh MW ; Van't Veer LJ ; Glas AM Breast Cancer Res Treat 2017[Jul]; 164 (2 ): 461-466 PMID28451965 show ga PURPOSE: Early-stage hormone-receptor positive breast cancer is treated with endocrine therapy and the recommended duration of these treatments has increased over time. While endocrine therapy is considered less of a burden to patients compared to chemotherapy, long-term adherence may be low due to potential adverse side effects as well as compliance fatigue. It is of high clinical utility to identify subgroups of breast cancer patients who may have excellent long-term survival without or with limited duration of endocrine therapy to aid in personalizing endocrine treatment. METHODS: We describe a new ultralow risk threshold for the 70-gene signature (MammaPrint) that identifies a group of breast cancer patients with excellent 20 year, long-term survival prognosis. Tumors of these patients are referred to as "indolent breast cancer." We used patient series on which we previously established and assessed the 70-gene signature high-low risk threshold. RESULTS: In an independent validation cohort, we show that patients with indolent breast cancer had 100% breast cancer-specific survival at 15 years of follow-up. CONCLUSIONS: Our data indicate that patients with indolent disease may be candidates for limited treatment with adjuvant endocrine therapy based on their very low risk of distant recurrences or death of breast cancer. |*Gene Regulatory Networks [MESH] |Breast Neoplasms/*genetics/*mortality [MESH] |Cohort Studies [MESH] |Female [MESH] |Genetic Predisposition to Disease [MESH] |Humans [MESH] |Kaplan-Meier Estimate [MESH] |Precision Medicine [MESH] |Prognosis [MESH] |Risk Assessment [MESH]A breast cancer gene signature for indolent disease (epmc).pdf DeepDyve Pubget Overpricing